Stock Market & Financial Investment News

News Breaks March 8, 2013 08:57 EDT ZTS Zoetis initiated with an Underperform at BMO Capital BMO Capital initiated Zoetis with an Underperform as it believes the company is overvalued given its low revenue growth. Price target is $28. News For ZTS From The Last 14 Days Check below for free stories on ZTS the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 23, 2013 12:37 EDT ZTS Options with increasing implied volatility: UNXL ZTS EWJ SWI Subscribe for More Information 11:24 EDT ZTS High option volume stocks: ZTS AMLP CTAS MNKD CYS Subscribe for More Information May 22, 2013 11:50 EDT ZTS High option volume stocks: ZTS AIRM GLDD GTXI MNKD Subscribe for More Information 08:59 EDT ZTS On The Fly: Pre-market Movers Subscribe for More Information 08:06 EDT ZTS Zoetis comments on Pfizer’s split-off plans for remaining interest Subscribe for More Information 08:04 EDT ZTS Pfizer announces plan to split-off remainder of Zoetis Subscribe for More Information 08:02 EDT ZTS Pfizer announces plan to split-off remainder of Zoetis Subscribe for More Information May 16, 2013 08:06 EDT ZTS Zoetis' Apoquel for allergic dogs approved by FDA Zoetis announced that the FDA has approved Apoquel (oclacitinib tablet) for the control of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs at least 12 months of age. Pruritus, or itching, is the most common sign of allergies in dogs. Sign up for a free trial to see the rest of the stories you've been missing.